AP2001002035A0 - Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. - Google Patents

Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.

Info

Publication number
AP2001002035A0
AP2001002035A0 APAP/P/2001/002035A AP2001002035A AP2001002035A0 AP 2001002035 A0 AP2001002035 A0 AP 2001002035A0 AP 2001002035 A AP2001002035 A AP 2001002035A AP 2001002035 A0 AP2001002035 A0 AP 2001002035A0
Authority
AP
ARIPO
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
APAP/P/2001/002035A
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AP2001002035A0 publication Critical patent/AP2001002035A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

This invention is the coadministration of acat and mmp inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regresion in a mammal.
APAP/P/2001/002035A 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. AP2001002035A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
AP2001002035A0 true AP2001002035A0 (en) 2001-03-31

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002035A AP2001002035A0 (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291L (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (en) 1999-12-01 2002-05-24 COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND ELONGATION OF NEURONS.
JP2003534239A (en) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド Novel succinate compounds, compositions, and methods of use and preparation
WO2002020009A1 (en) * 2000-09-01 2002-03-14 Sankyo Company, Limited Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP4617449B2 (en) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド N-hydroxyamide derivative having antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EA001561B1 (en) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Biphenylsulfonamide matrix metalloproteinase inhibitors
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ID30030A (en) 2001-11-01
AU4701799A (en) 2000-02-14
IS5809A (en) 2001-01-12
HUP0102880A3 (en) 2002-11-28
CZ2001126A3 (en) 2002-01-16
TR200100205T2 (en) 2001-05-21
NO20010291D0 (en) 2001-01-18
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03
CN1310629A (en) 2001-08-29
YU3501A (en) 2005-06-10
PL346011A1 (en) 2002-01-14
ZA200100294B (en) 2002-01-10
NO20010291L (en) 2001-01-18
KR20010083134A (en) 2001-08-31
CA2335062A1 (en) 2000-02-03
OA11584A (en) 2004-07-20
EP1098662A2 (en) 2001-05-16
EA200100153A1 (en) 2001-08-27
BG105162A (en) 2001-12-29
HUP0102880A2 (en) 2002-06-29
EE200100046A (en) 2002-06-17
SK502001A3 (en) 2002-06-04
BR9912296A (en) 2001-04-17
IL140982A0 (en) 2002-02-10
JP2002521328A (en) 2002-07-16
WO2000004892A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
AP2001002035A0 (en) Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.
EP1100392A4 (en) Methods and devices for reducing the mineral content of vascular calcified lesions
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
EP1147287A4 (en) Procedures and equipment for profiling and jointing of pipes
HUP9904024A3 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
AU3103099A (en) Microbubble-based ultrasonic contrast agents for pressure measurements
MXPA01005165A (en) Dual mode emergency braking apparatus and method of use thereof.
HK1038198A1 (en) Use of eletriptan in the manufacture of a medicament for the prevention of migraine recurrence.
AU3364899A (en) Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer
AU4307800A (en) New indication for use of antiepileptic agents and medicines
HUP9801075A3 (en) Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses
IT1302813B1 (en) DEVICE FOR THE DIRECT REDUCTION OF IRON OXIDES AND RELATED PROCEDURE
AU4144099A (en) Use of an agent for the prevention of gum disease
GB0029207D0 (en) Brake shoe and internal shoe drum brake
AU7833298A (en) New human carboxypeptidase inhibitor
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
HUP9903964A3 (en) Methods and compositions for preventing or retarding the development of atherosclerotic lesions
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
AU2001243477A1 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ZA200207107B (en) New combination of a betablocker and a cholesterol-lowering agent.
MXPA02011810A (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy.
IT1321047B1 (en) PROCEDURE AND DEVICE FOR THE DETECTION OF THE DEACTIVATION OF A BRAKING DEVICE, PARTICULARLY FOR A
GB9806485D0 (en) Multipositional paediatric walking aid